Medivir AB, of Stockholm, Sweden, said a Phase I trial has been initiated for MIV-711, a cathepsin K inhibitor to treat bone disorders such as osteoporosis, osteoarthritis and bone metastases. MIV-711 will be administered as single-ascending oral doses to healthy volunteers, followed by daily doses for seven days.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter